GlassScriptPhysician profile
Hanna Suzanne Cunningham
NPI 1689179251
$5,464.12
in general payments reported to CMS, 2019-2025
37 companies · $521 in 2025
The $521 reported for 2025 was more than what 76% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,111 · 2022: $1,778 · 2023: $603 · 2024: $451 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,248.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $753.98 | 2021-2025 | |
| Lilly USA, LLC | $369.46 | 2021-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $339.27 | 2022 | |
| Glaxosmithkline, LLC. | $283.54 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $253.64 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $184.02 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $169.38 | 2021-2023 | Rexulti |
| Amgen INC. | $160.20 | 2021-2024 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $147.79 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $140.33 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.80 | 2021-2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $137.10 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $113.73 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.97 | 2024-2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $96.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.88 | 2021-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $80.30 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.63 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $77.13 | 2024-2025 | Voquezna |
| Pfizer INC. | $61.23 | 2021-2025 | |
| Insulet Corporation | $60.52 | 2022-2023 | Omnipod |
| Astellas Pharma US INC | $47.70 | 2021 | |
| Dexcom, INC. | $45.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.71 | 2021 | |
| Silk Road Medical, INC. | $37.61 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Exact Sciences Corporation | $29.17 | 2024-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $26.80 | 2022-2023 | Contrave |
| Amarin Pharma, INC. | $22.41 | 2021 | |
| Genentech USA, INC. | $22.02 | 2021 | |
| Axsome Therapeutics, INC. | $18.87 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $18.60 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $15.89 | 2021 | |
| Sanofi Pasteur INC. | $14.18 | 2022 | |
| Sumitomo Pharma America, INC. | $13.80 | 2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $13.32 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanna Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.